

# Brian J Lipworth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6290807/publications.pdf>

Version: 2024-02-01

566  
papers

19,779  
citations

11651

70  
h-index

22832

112  
g-index

571  
all docs

571  
docs citations

571  
times ranked

12630  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Adverse Effects of Inhaled Corticosteroid Therapy. Archives of Internal Medicine, 1999, 159, 941.	3.8	819
2	Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. Journal of Allergy and Clinical Immunology, 2020, 146, 128-136.e4.	2.9	783
3	Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet, The, 2005, 365, 167-175.	13.7	376
4	Association between $\beta_2$ -adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet, The, 1997, 350, 995-999.	13.7	347
5	Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respiratory Medicine, 1994, 88, 363-368.	2.9	258
6	Effect of $\beta$ blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ, The, 2011, 342, d2549-d2549.	6.0	234
7	Respiratory Symptoms, Pulmonary Function, and Markers of Inflammation Among Bar Workers Before and After a Legislative Ban on Smoking in Public Places. JAMA - Journal of the American Medical Association, 2006, 296, 1742.	7.4	225
8	Gene-Environment Interaction in the Onset of Eczema in Infancy: Filaggrin Loss-of-Function Mutations Enhanced by Neonatal Cat Exposure. PLoS Medicine, 2008, 5, e131.	8.4	215
9	Leukotriene-receptor antagonists. Lancet, The, 1999, 353, 57-62.	13.7	212
10	Safety of Inhaled and Intranasal Corticosteroids. Drug Safety, 2000, 23, 11-33.	3.2	189
11	Effects of Hypercapnia on Hemodynamic, Inotropic, Lusitropic, and Electrophysiologic Indices in Humans. Chest, 1996, 109, 1215-1221.	0.8	188
12	Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet, The, 1995, 346, 201-206.	13.7	187
13	Pharmacokinetics of inhaled drugs. British Journal of Clinical Pharmacology, 1996, 42, 697-705.	2.4	165
14	Portable Exhaled Nitric Oxide Measurement. Chest, 2007, 131, 410-414.	0.8	155
15	C-Reactive Protein. Chest, 1995, 108, 1288-1291.	0.8	154
16	Treatment of Chronic Rhinosinusitis With Nasal Polyposis With Oral Steroids Followed by Topical Steroids. Annals of Internal Medicine, 2011, 154, 293.	3.9	150
17	Tachyphylaxis to Systemic But Not to Airway Responses during Prolonged Therapy with High Dose Inhaled Salbutamol in Asthmatics. The American Review of Respiratory Disease, 1989, 140, 586-592.	2.9	147
18	Systemic Corticosteroid Rapidly Reverses Bronchodilator Subsensitivity Induced by Formoterol in Asthmatic Patients. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 28-35.	5.6	146

#	ARTICLE	IF	CITATIONS
19	Arginine-16 $\beta_2$ adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. <i>Thorax</i> , 2006, 61, 940-944.	5.6	142
20	Unlocking the quiet zone: the small airway asthma phenotype. <i>Lancet Respiratory Medicine</i> , 2014, 2, 497-506.	10.7	140
21	Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients.. <i>Thorax</i> , 1996, 51, 262-266.	5.6	137
22	Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. <i>Thorax</i> , 1997, 52, 476-482.	5.6	132
23	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	2.9	128
24	Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma. <i>American Journal of Medicine</i> , 2000, 108, 269-275.	1.5	125
25	Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients.. <i>Thorax</i> , 1995, 50, 497-504.	5.6	122
26	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021, 9, 699-711.	10.7	122
27	Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 94, 465-472.	1.0	121
28	New perspectives on inhaled drug delivery and systemic bioactivity.. <i>Thorax</i> , 1995, 50, 105-110.	5.6	119
29	The arginine-16 $\beta_2$ -adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 68-75.	2.4	117
30	Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 328-335.	2.9	114
31	Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. <i>American Heart Journal</i> , 1994, 127, 1635-1636.	2.7	112
32	A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. <i>Clinical and Experimental Allergy</i> , 2001, 31, 616-624.	2.9	110
33	Airway Subsensitivity with Long-Acting $\beta_2$ -Agonists Is There Cause for Concern?. <i>Drug Safety</i> , 1997, 16, 295-308.	3.2	109
34	Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 598-604.	2.9	109
35	Bronchodilator Response to Albuterol After Regular Formoterol and Effects of Acute Corticosteroid Administration. <i>Chest</i> , 2000, 117, 156-162.	0.8	108
36	Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. <i>American Journal of Medicine</i> , 1994, 97, 29-37.	1.5	107

#	ARTICLE	IF	CITATIONS
37	Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. <i>Thorax</i> , 1997, 52, 55-58.	5.6	107
38	Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal axis activity. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 101, 470-474.	2.9	107
39	Evaluation of Salmeterol or Montelukast as Second-Line Therapy for Asthma Not Controlled With Inhaled Corticosteroids. <i>Chest</i> , 2001, 119, 1021-1026.	0.8	107
40	Effects of Montelukast on Surrogate Inflammatory Markers in Corticosteroid-treated Patients with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 1232-1238.	5.6	104
41	Effects of Treatment with Formoterol on Bronchoprotection against Methacholine. <i>American Journal of Medicine</i> , 1998, 104, 431-438.	1.5	101
42	Modulation of airway reactivity and peak flow variability in asthmatics receiving the oral contraceptive pill. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 155, 1273-1277.	5.6	100
43	The case for impulse oscillometry in the management of asthma in children and adults. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 664-671.	1.0	99
44	Therapeutic implications of non-genomic glucocorticoid activity. <i>Lancet</i> , The, 2000, 356, 87-89.	13.7	96
45	Adrenergic $\beta_2$ -receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 1188-1194.e3.	2.9	96
46	Effects of airway calibre on lung delivery of nebulised salbutamol. <i>Thorax</i> , 1997, 52, 1036-1039.	5.6	94
47	Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 293-300.	10.7	94
48	C-Reactive Protein in Simple Community-Acquired Pneumonia. <i>Chest</i> , 1995, 107, 1028-1031.	0.8	90
49	Assessment of Small-Airways Disease Using Alveolar Nitric Oxide and Impulse Oscillometry in Asthma and COPD. <i>Lung</i> , 2011, 189, 121-129.	3.3	90
50	The Impact of Tiotropium on Mortality and Exacerbations When Added to Inhaled Corticosteroids and Long-Acting $\beta_2$ -Agonist Therapy in COPD. <i>Chest</i> , 2012, 141, 81-86.	0.8	88
51	Adverse Respiratory Effect of Acute $\beta_2$ -Blocker Exposure in Asthma. <i>Chest</i> , 2014, 145, 779-786.	0.8	88
52	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
53	The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 1467-1478.	10.7	84
54	Effects of Genetic Polymorphism on Ex Vivo and In Vivo Function of $\beta_2$ -Adrenoceptors in Asthmatic Patients. <i>Chest</i> , 1999, 115, 324-328.	0.8	83

#	ARTICLE	IF	CITATIONS
55	Adrenal Suppression with Dry Powder Formulations of Fluticasone Propionate and Mometasone Furoate. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 960-966.	5.6	83
56	The minimal clinically important difference in allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2010, 40, 242-250.	2.9	83
57	Airway and Systemic Effects of Inhaled Corticosteroids in Asthma: Dose Response Relationship. <i>Pulmonary Pharmacology</i> , 1996, 9, 19-27.	0.6	82
58	Antiasthmatic Effects of Mediator Blockade versus Topical Corticosteroids in Allergic Rhinitis and Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1297-1301.	5.6	82
59	Screening for Bronchial Hyperresponsiveness Using Methacholine and Adenosine Monophosphate. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1318-1322.	5.6	82
60	Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2001, 31, 61-68.	2.9	82
61	Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. <i>Thorax</i> , 1997, 52, 608-611.	5.6	80
62	Childhood asthma exacerbations and the Arg16 G2-receptor polymorphism: A meta-analysis stratified by treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 107-113.e5.	2.9	80
63	A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. <i>Respiratory Medicine</i> , 2007, 101, 1218-1228.	2.9	78
64	Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. <i>European Journal of Clinical Pharmacology</i> , 1989, 36, 239-245.	1.9	77
65	Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). <i>Thorax</i> , 1994, 49, 762-770.	5.6	77
66	β <sub>2</sub> -Adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 101, 337-341.	2.9	77
67	Fluticasone Reverses Oxymetazoline-induced Tachyphylaxis of Response and Rebound Congestion. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 19-24.	5.6	76
68	Airway and Systemic Effects of Hydrofluoroalkane Formulations of High-Dose Ciclesonide and Fluticasone in Moderate Persistent Asthma. <i>Chest</i> , 2005, 127, 851-860.	0.8	75
69	Tailored second-line therapy in asthmatic children with the Arg16 genotype. <i>Clinical Science</i> , 2013, 124, 521-528.	4.3	74
70	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3997-4004.	3.8	74
71	Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. <i>Thorax</i> , 1996, 51, 981-984.	5.6	73
72	Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. <i>Thorax</i> , 1996, 51, 689-693.	5.6	73

#	ARTICLE	IF	CITATIONS
73	Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2006, 36, 676-684.	2.9	72
74	A Bolus of Inhaled Budesonide Rapidly Reverses Airway Subsensitvity and $\beta_2$ -Adrenoceptor Down-regulation After Regular Inhaled Formoterol. <i>Chest</i> , 1999, 115, 623-628.	0.8	71
75	Are we overlooking persistent small airways dysfunction in community-managed asthma?. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 109, 185-189.e2.	1.0	71
76	Clinical pharmacology of $\beta_3$ -adrenoceptors. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 291-300.	2.4	70
77	Effects of Once-Daily Formoterol and Budesonide Given Alone or in Combination on Surrogate Inflammatory Markers in Asthmatic Adults. <i>Chest</i> , 2000, 118, 1049-1058.	0.8	70
78	Influence of sex steroid hormones on the regulation of lymphocyte beta $2$ -adrenoceptors during the menstrual cycle.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 583-588.	2.4	69
79	24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. <i>Thorax</i> , 1999, 54, 20-26.	5.6	69
80	Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, e97-e109.	5.6	69
81	Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 45-48.	2.4	67
82	Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. <i>BMC Medicine</i> , 2017, 15, 18.	5.5	67
83	Paradoxical Down-Regulation and Desensitization of $\beta_2$ -Adrenoceptors by Exogenous Progesterone in Female Asthmatics. <i>Chest</i> , 1997, 111, 847-851.	0.8	66
84	Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. <i>Cardiovascular Research</i> , 1997, 33, 201-208.	3.8	65
85	Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. <i>Clinical and Experimental Allergy</i> , 2000, 30, 833-838.	2.9	65
86	Underuse of $\beta_2$ -blockers in heart failure and chronic obstructive pulmonary disease. <i>Heart</i> , 2016, 102, 1909-1914.	2.9	65
87	Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 40-45.e10.	2.9	64
88	Adverse Effects of Hypoxaemia on Diastolic Filling in Humans. <i>Clinical Science</i> , 1995, 89, 165-169.	4.3	62
89	Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. <i>Annals of Allergy, Asthma and Immunology</i> , 2003, 90, 194-198.	1.0	62
90	NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 828-835.	5.7	62

#	ARTICLE	IF	CITATIONS
91	A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects [see comments]. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 527-532.	2.4	61
92	A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 103, 88-92.	2.9	61
93	Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2002, 32, 1504-1509.	2.9	61
94	Small airway dysfunction is associated with poorer asthma control. <i>European Respiratory Journal</i> , 2014, 44, 1353-1355.	6.7	61
95	Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. <i>European Respiratory Journal</i> , 1998, 12, 580-584.	6.7	60
96	Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2001, 87, 344-349.	1.0	60
97	Beta-blockers in COPD: time for reappraisal. <i>European Respiratory Journal</i> , 2016, 48, 880-888.	6.7	60
98	Effects of adding a leukotriene antagonist or a long-acting beta2-agonist in asthmatic patients with the glycine-16 beta2-adrenoceptor genotype. <i>American Journal of Medicine</i> , 2000, 109, 114-121.	1.5	59
99	Lisinopril Attenuates Acute Hypoxic Pulmonary Vasoconstriction in Humans. <i>Chest</i> , 1996, 109, 424-429.	0.8	58
100	Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 68-74.	2.9	58
101	Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade.. <i>British Journal of Clinical Pharmacology</i> , 1989, 28, 95-102.	2.4	57
102	Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 333-336.	2.4	57
103	Inhaled Corticosteroid Dose Response Using Domiciliary Exhaled Nitric Oxide in Persistent Asthma. <i>Chest</i> , 2012, 142, 1553-1561.	0.8	57
104	Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2001, 31, 61-68.	2.9	57
105	A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2002, 32, 126-132.	2.9	56
106	A Randomized Primary Care Trial of Steroid Titration Against Mannitol in Persistent Asthma. <i>Chest</i> , 2012, 141, 607-615.	0.8	56
107	Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children.. <i>Thorax</i> , 1996, 51, 941-943.	5.6	55
108	Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 11-17.	2.4	55



#	ARTICLE	IF	CITATIONS
109	Does body mass index influence responsiveness to inhaled corticosteroids in persistent asthma?. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 108, 237-242.	1.0	55
110	Cardiopulmonary effects of endothelin-1 in man. <i>Cardiovascular Research</i> , 1997, 33, 378-386.	3.8	54
111	Comparison of bronchodilator response in patients with asthma and healthy subjects using spirometry and oscillometry. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 107, 317-322.	1.0	54
112	Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Cor Pulmonale. <i>Chest</i> , 1996, 110, 1220-1225.	0.8	53
113	Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. <i>Clinical and Experimental Allergy</i> , 2003, 33, 783-788.	2.9	53
114	Beta $\beta$ adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma.. <i>British Journal of Clinical Pharmacology</i> , 1988, 26, 527-533.	2.4	50
115	Risks Versus Benefits of Inhaled $\beta$ 2-Agonists in the Management of Asthma. <i>Drug Safety</i> , 1992, 7, 54-70.	3.2	50
116	Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers.. <i>Thorax</i> , 1997, 52, 849-852.	5.6	50
117	Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. <i>Thorax</i> , 1997, 52, 686-689.	5.6	50
118	Treatment of acute asthma. <i>Lancet, The</i> , 1997, 350, S18-S23.	13.7	50
119	Randomized Placebo-controlled Trial to Evaluate Chronic Dosing Effects of Propranolol in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1308-1314.	5.6	50
120	Dose-Response of Inhaled Drugs in Asthma. <i>Clinical Pharmacokinetics</i> , 1997, 32, 58-74.	3.5	49
121	Functional Antagonism With Formoterol and Salmeterol in Asthmatic Patients Expressing the Homozygous Glycine-16 $\beta$ 2-Adrenoceptor Polymorphism. <i>Chest</i> , 2000, 118, 321-328.	0.8	48
122	Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2000, 85, 111-114.	1.0	47
123	Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 494-500.	2.4	47
124	Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta2-adrenoceptor blockade. <i>European Journal of Clinical Pharmacology</i> , 1989, 37, 297-300.	1.9	46
125	Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. <i>American Journal of Medicine</i> , 1989, 86, 653-657.	1.5	46
126	Vasoconstrictor Effects of Angiotensin II on the Pulmonary Vascular Bed. <i>Chest</i> , 1994, 105, 1360-1364.	0.8	46



#	ARTICLE	IF	CITATIONS
127	Additive Bronchoprotective and Bronchodilator Effects With Single Doses of Salmeterol and Montelukast in Asthmatic Patients Receiving Inhaled Corticosteroids. <i>Chest</i> , 2000, 117, 950-953.	0.8	46
128	Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a beclomethasone alone. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 929-935.	2.9	46
129	Effects of hydrofluoroalkane formulations of ciclesonide 400 ug once daily vs fluticasone 250 ug twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 26-33.	2.4	46
130	Filaggrin null mutations are associated with increased asthma exacerbations in children and young adults. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1211-1217.	5.7	46
131	The role of pulmonary arterial stiffness in COPD. <i>Respiratory Medicine</i> , 2015, 109, 1381-1390.	2.9	46
132	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	5.7	46
133	Comparison of the extrapulmonary $\beta_2$ -adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose inhaler and modified actuator device. <i>British Journal of Clinical Pharmacology</i> , 1993, 36, 445-450.	2.4	45
134	C-type natriuretic peptide levels in cor pulmonale and in congestive heart failure.. <i>Thorax</i> , 1994, 49, 1247-1249.	5.6	45
135	Dose-response Effect for Adrenal Suppression with Repeated Twice Daily Inhaled Fluticasone Propionate and Triamcinolone Acetonide in Adult Asthmatics. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 156, 1274-1277.	5.6	45
136	Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol.. <i>Thorax</i> , 1995, 50, 1062-1066.	5.6	44
137	Dose Response to Inhaled Corticosteroids: Benefits and Risks. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1998, 19, 625-646.	2.1	44
138	Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2004, 34, 650-653.	2.9	44
139	What can we learn about COPD from impulse oscillometry?. <i>Respiratory Medicine</i> , 2018, 139, 106-109.	2.9	44
140	Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?. <i>British Journal of Clinical Pharmacology</i> , 1992, 33, 129-138.	2.4	43
141	Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 247-249.	2.4	43
142	Asthma and Cushing's Syndrome. <i>Chest</i> , 2000, 117, 593-594.	0.8	43
143	Allergic inflammation in the unified airway: start with the nose. <i>Thorax</i> , 2000, 55, 878-881.	5.6	43
144	Butterbur, a herbal remedy, attenuates adenosine monophosphate induced nasal responsiveness in seasonal allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2003, 33, 882-886.	2.9	43

#	ARTICLE	IF	CITATIONS
145	A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2004, 34, 646-649.	2.9	43
146	Fluticasone/Salmeterol Combination Confers Benefits in People With Asthma Who Smoke. <i>Chest</i> , 2012, 141, 330-338.	0.8	43
147	Evaluation of the Effect of a Large Volume Spacer on the Systemic Bioactivity of Fluticasone Propionate Metered-Dose Inhaler. <i>Chest</i> , 1999, 116, 935-940.	0.8	42
148	Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 814-822.	2.4	42
149	Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients.. <i>Thorax</i> , 1995, 50, 54-61.	5.6	41
150	Effects of butterbur treatment in intermittent allergic rhinitis: a placebo-controlled evaluation. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 93, 56-60.	1.0	41
151	Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 363-369.	2.4	40
152	Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 579-585.	2.4	40
153	In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 103, 816-822.	2.9	40
154	Effects of Adding Either a Leukotriene Receptor Antagonist or Low-Dose Theophylline to a Low or Medium Dose of Inhaled Corticosteroid in Patients With Persistent Asthma. <i>Chest</i> , 2002, 122, 151-159.	0.8	40
155	Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2003, 58, 762-766.	5.7	40
156	Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1220-1230.	2.9	40
157	Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1798-1801.	3.8	40
158	Effects of exogenous female sex-steroid hormones on lymphocyte $\beta_2$ -adrenoceptors in normal females. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 414-416.	2.4	39
159	Comparison of the Effects of Prolonged Treatment with Low and High Doses of Inhaled Terbutaline on Beta-Adrenoceptor Responsiveness in Patients with Chronic Obstructive Pulmonary Disease. <i>The American Review of Respiratory Disease</i> , 1990, 142, 338-342.	2.9	38
160	Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans.. <i>British Journal of Clinical Pharmacology</i> , 1995, 40, 585-590.	2.4	38
161	Fortnightly review: Modern drug treatment of chronic asthma. <i>BMJ: British Medical Journal</i> , 1999, 318, 380-384.	2.3	38
162	Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 422-426.	2.4	38

#	ARTICLE	IF	CITATIONS
163	Assessment of Spirometry and Impulse Oscillometry in Relation to Asthma Control. <i>Lung</i> , 2015, 193, 47-51.	3.3	38
164	Hypoxaemia and release of endothelin-1. <i>Thorax</i> , 1995, 50, 1308-1310.	5.6	37
165	Angiotensin 11 Receptor Blockade and Effects on Pulmonary Hemodynamics and Hypoxic Pulmonary Vasoconstriction in Humans. <i>Chest</i> , 1996, 110, 698-703.	0.8	37
166	Systemic Bioactivity Profiles of Oral Prednisolone and Nebulized Budesonide in Adult Asthmatics. <i>Chest</i> , 1998, 114, 1022-1027.	0.8	37
167	Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids. <i>Lancet</i> , The, 1999, 353, 2128.	13.7	37
168	Sensitivity of impulse oscillometry and spirometry in beta-blocker induced bronchoconstriction and beta-agonist bronchodilatation in asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 109, 412-415.	1.0	37
169	Targeting the small airways asthma phenotype: if we can reach it, should we treat it?. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 110, 233-239.	1.0	37
170	Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. <i>Thorax</i> , 1993, 48, 656-658.	5.6	36
171	Bronchoprotective Effects of Leukotriene Receptor Antagonists in Asthma. <i>Chest</i> , 2002, 122, 146-150.	0.8	36
172	Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in Patients with asthma. <i>European Journal of Clinical Pharmacology</i> , 1989, 37, 567-571.	1.9	36
173	Investigations on the renin-angiotensin system in acute severe asthma. <i>European Respiratory Journal</i> , 1997, 10, 2766-2771.	6.7	35
174	5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 187-190.	1.9	35
175	Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. <i>European Respiratory Journal</i> , 2004, 24, 226-230.	6.7	35
176	Steroid sparing effects of intranasal corticosteroids in asthma and allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 359-367.	5.7	35
177	Response to salbutamol in patients with mild asthma treated with nadolol. <i>European Respiratory Journal</i> , 2010, 36, 963-965.	6.7	35
178	Does size really matter?: Relationship of particle size to lung deposition and exhaled fraction. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 2013-2014.e1.	2.9	35
179	Relationship between fractional exhaled nitric oxide and nasal nitric oxide in airways disease. <i>Annals of Allergy, Asthma and Immunology</i> , 2010, 105, 162-167.	1.0	34
180	Emerging role of long acting muscarinic antagonists for asthma. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 55-62.	2.4	34

#	ARTICLE	IF	CITATIONS
181	Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. <i>International Journal of COPD</i> , 2018, Volume 13, 2969-2984.	2.3	34
182	Scottish consensus statement on the role of FeNO in adult asthma. <i>Respiratory Medicine</i> , 2019, 155, 54-57.	2.9	34
183	Cross tolerance to salbutamol occurs independently of $\beta_2$ adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. <i>Thorax</i> , 2004, 59, 662-667.	5.6	33
184	Clinical Pharmacokinetics of Drugs Administered Buccally and Sublingually. <i>Clinical Pharmacokinetics</i> , 1991, 21, 83-94.	3.5	32
185	Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans.. <i>Thorax</i> , 1995, 50, 183-185.	5.6	32
186	Benefit-Risk Assessment of Long-Acting $\beta_2$ -Agonists in Asthma. <i>Drug Safety</i> , 2004, 27, 243-270.	3.2	32
187	Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3363-3370.	3.8	32
188	The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.. <i>British Journal of Clinical Pharmacology</i> , 1995, 40, 11-18.	2.4	31
189	Effects of Low and High Doses of Inhaled Flunisolide and Triamcinolone Acetonide on Basal and Dynamic Measures of Adrenocortical Activity in Healthy Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 922-925.	3.6	31
190	Airway dysfunction in nasal polyposis: a spectrum of asthmatic disease?. <i>Clinical and Experimental Allergy</i> , 2011, 41, 1379-1385.	2.9	31
191	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EGAS <sup>2</sup> LEN consensus. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2354-2366.	5.7	31
192	Tolerance with beta $\beta_2$ -adrenoceptor agonists: time for reappraisal.. <i>British Journal of Clinical Pharmacology</i> , 1995, 39, 109-118.	2.4	30
193	Concomitant inhaled corticosteroid resensitises cardiac $\beta_2$ -adrenoceptors in the presence of long-acting $\beta_2$ -agonist therapy. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 377-381.	1.9	30
194	Targeting Downstream Type 2 Cytokines or Upstream Epithelial Alarmins for Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1497-1505.	3.8	30
195	Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2001, 31, 61-8.	2.9	30
196	The effects of angiotensin II on circulating levels of natriuretic peptides.. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 139-142.	2.4	29
197	Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 866-868.	2.4	29
198	Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 11-15.	1.9	29

#	ARTICLE	IF	CITATIONS
199	Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2003, 58, 602-607.	5.7	29
200	Does Bronchial Hyperresponsiveness in Asthma Matter?. <i>Journal of Asthma</i> , 2004, 41, 247-258.	1.7	29
201	Combined mediator blockade or topical steroid for treating the unified allergic airway. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 73-80.	5.7	29
202	Evaluation of partial $\beta$ -adrenoceptor agonist activity. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 9-14.	2.4	29
203	Systemic beta-adrenoceptor responses to salbutamol given by metered-dose inhaler alone and with pear shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects.. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 837-842.	2.4	28
204	Effects of Inhaled Fluticasone Propionate and Oral Prednisolone on Lymphocyte $\beta_2$ -Adrenoceptor Function in Asthmatic Patients. <i>Chest</i> , 1996, 109, 343-347.	0.8	28
205	Evaluation of Corticotropin Releasing Factor Stimulation and Basal Markers of Hypothalamic-Pituitary-Adrenal Axis Suppression in Asthmatic Patients. <i>Chest</i> , 1997, 112, 1248-1252.	0.8	28
206	Concomitant Administration of Low-Dose Prednisolone Protects Against In Vivo $\beta_2$ -Adrenoceptor Subsensitization Induced by Regular Formoterol. <i>Chest</i> , 1998, 113, 34-41.	0.8	28
207	Differences in lung bioavailability between different propellants for fluticasone propionate. <i>Lancet</i> , 1999, 354, 1357-1358.	13.7	28
208	Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 337-341.	2.9	28
209	Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 34-39.	2.4	28
210	A comparison of 2 extrafine hydrofluoroalkane-134a beclomethasone formulations on methacholine hyperresponsiveness. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 96, 422-430.	1.0	28
211	Long-acting $\beta_2$ -adrenoceptor agonists: a smart choice for asthma?. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 257-262.	8.7	28
212	Disconnect between effects of mepolizumab on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1714-1716.	3.8	28
213	Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.. <i>British Journal of Clinical Pharmacology</i> , 1992, 34, 337-343.	2.4	27
214	Lung Delivery of Salbutamol Given by Breath Activated Pressurized Aerosol and Dry Powder Inhaler Devices. <i>Pulmonary Pharmacology and Therapeutics</i> , 1997, 10, 211-214.	2.6	27
215	Determinants of airway hyperresponsiveness in mild asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2003, 90, 560-563.	1.0	27
216	Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 93, 253-258.	1.0	27

#	ARTICLE	IF	CITATIONS
217	$\hat{I}^2$ blockers for asthma: a double-edged sword. <i>Lancet, The</i> , 2009, 373, 104-105.	13.7	27
218	Effects of chlorine and exercise on the unified airway in adolescent elite Scottish swimmers. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 269-273.	5.7	27
219	Utility of impulse oscillometry in patients with moderate to severe persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 601-603.	2.9	27
220	Safety and efficacy of the Russian COVID-19 vaccine: more information needed. <i>Lancet, The</i> , 2020, 396, e53.	13.7	27
221	Adrenocortical activity with repeated administration of one-daily inhaled fluticasone propionate and budesonide in asthmatic adults. <i>European Journal of Clinical Pharmacology</i> , 1998, 53, 317-320.	1.9	26
222	Butterbur, a herbal remedy, confers complementary anti-inflammatory activity in asthmatic patients receiving inhaled corticosteroids. <i>Clinical and Experimental Allergy</i> , 2004, 34, 110-114.	2.9	26
223	Left Ventricular Hypertrophy in COPD Without Hypoxemia. <i>Chest</i> , 2013, 143, 91-97.	0.8	26
224	Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.. <i>Thorax</i> , 1996, 51, 54-58.	5.6	25
225	Lung bioavailability of generic and innovator salbutamol metered dose inhalers.. <i>Thorax</i> , 1996, 51, 325-326.	5.6	25
226	Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. <i>Clinical Endocrinology</i> , 1999, 50, 329-335.	2.4	25
227	Pharmacokinetics and systemic $\hat{I}^2$ -adrenoceptor-mediated responses to inhaled salbutamol. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 359-362.	2.4	25
228	Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 93-95.	2.4	25
229	Relationship of skin-prick reactivity to aeroallergens and hyperresponsiveness to challenges with methacholine and adenosine monophosphate. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2003, 58, 46-52.	5.7	25
230	Airway-stabilizing effect of long-acting $\hat{A}^2$ -agonists as add-on therapy to inhaled corticosteroids. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 435-440.	0.5	25
231	Pharmacokinetic and pharmacodynamic comparison of hydrofluoroalkane and chlorofluorocarbon formulations of budesonide. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 504-513.	2.4	25
232	Current appraisal of single inhaler triple therapy in COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 3003-3009.	2.3	25
233	A dose-ranging study to evaluate the $\hat{I}^1$ -adrenoceptor selectivity of bisoprolol. <i>European Journal of Clinical Pharmacology</i> , 1991, 40, 135-139.	1.9	25
234	Left Ventricular Systolic Performance During Acute Hypoxemia. <i>Chest</i> , 1995, 108, 899-902.	0.8	24

#	ARTICLE	IF	CITATIONS
235	Lung delivery of non- $\beta$ -CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 160-163.	2.4	24
236	Therapeutic Ratio of Hydrofluoroalkane and Chlorofluorocarbon Formulations of Fluticasone Propionate. <i>Chest</i> , 2002, 122, 618-623.	0.8	24
237	Long-Acting $\beta_2$ -Agonists in Asthma. <i>Drug Safety</i> , 2006, 29, 647-656.	3.2	24
238	Usefulness of impulse oscillometry for the assessment of airway hyperresponsiveness in mild-to-moderate adult asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 17-20.	1.0	24
239	Benefit:Risk Profile of Budesonide in Obstructive Airways Disease. <i>Drugs</i> , 2019, 79, 1757-1775.	10.9	24
240	Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 1997, 53, 33-37.	1.9	23
241	Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices. <i>European Journal of Clinical Pharmacology</i> , 1997, 53, 47-49.	1.9	23
242	Adenosine monophosphate bronchial provocation and the actions of asthma therapy. <i>Clinical and Experimental Allergy</i> , 2003, 33, 287-294.	2.9	23
243	Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 714-719.	2.4	23
244	The effects of butterbur on the histamine and allergen cutaneous response. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 92, 250-254.	1.0	23
245	Is small airways dysfunction related to asthma control and type 2 inflammation?. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 631-632.	1.0	23
246	Late Relapse of Desquamative Interstitial Pneumonia. <i>The American Review of Respiratory Disease</i> , 1987, 136, 1253-1255.	2.9	22
247	Hypokalemic and ECG Sequelae of Combined Beta-Agonist/Diuretic Therapy. <i>Chest</i> , 1990, 98, 811-815.	0.8	22
248	Emerging role of antileukotriene therapy in allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2001, 31, 1813-1821.	2.9	22
249	<i>In vivo</i> comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 191-198.	2.4	22
250	Effect of systemic steroids on humming nasal nitric oxide in chronic rhinosinusitis with nasal polyposis. <i>Annals of Allergy, Asthma and Immunology</i> , 2010, 105, 412-417.	1.0	22
251	Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone.. <i>Thorax</i> , 1995, 50, 134-138.	5.6	21
252	Dose-response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 751-756. <sup>2,9</sup>		21



#	ARTICLE	IF	CITATIONS
253	Add-on therapy with montelukast or formoterol in patients with the glycine-16 $\beta_2$ -receptor genotype. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 104-111.	2.4	21
254	Allergen sensitization and bronchial hyper-responsiveness to adenosine monophosphate in asthmatic patients. <i>Clinical and Experimental Allergy</i> , 2003, 33, 1405-1408.	2.9	21
255	Reproducibility of response to nasal lysine-aspirin challenge in patients with aspirin-induced asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 93, 185-188.	1.0	21
256	Differential anti-inflammatory effects of large and small particle size inhaled corticosteroids in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 661-667.	5.7	21
257	Supervised step-down of inhaled corticosteroids in the community – An observational study. <i>Respiratory Medicine</i> , 2011, 105, 558-565.	2.9	21
258	Relationships between impulse oscillometry, spirometry and dyspnoea in COPD. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2012, 42, 111-115.	0.6	21
259	I Say IOS You Say AOS: Comparative Bias in Respiratory Impedance Measurements. <i>Lung</i> , 2019, 197, 473-481.	3.3	21
260	Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy. <i>Clinical Science</i> , 1999, 96, 253-9.	4.3	21
261	Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol. <i>European Journal of Clinical Pharmacology</i> , 1990, 38, 203-5.	1.9	20
262	Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects. <i>European Journal of Clinical Pharmacology</i> , 1991, 40, 255-260.	1.9	20
263	Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate. <i>Thorax</i> , 1999, 54, 614-617.	5.6	20
264	Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous $\beta_2$ -adrenoceptor haplotypes at positions 16 and 27. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 100-104.	2.4	20
265	Non-Invasive Measurement of Airway Inflammation in Asthma. <i>Journal of Asthma</i> , 2006, 43, 407-415.	1.7	20
266	Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 20-26.	2.4	20
267	Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol. <i>Thorax</i> , 1996, 51, 585-589.	5.6	19
268	Effects of frusemide and hypoxia on the pulmonary vascular bed in man. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 309-313.	2.4	19
269	Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 310-313.	2.4	19
270	Symptoms, spirometry, exhaled nitric oxide, and asthma exacerbations in clinical practice. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 101, 248-255.	1.0	19

#	ARTICLE	IF	CITATIONS
271	Disconnect between standardized field-based testing and mannitol challenge in Scottish elite swimmers. <i>Clinical and Experimental Allergy</i> , 2010, 40, 731-737.	2.9	19
272	Repeated Dosing Effects of Mediator Antagonists in Inhaled Corticosteroid-Treated Atopic Asthmatic Patients. <i>Chest</i> , 2004, 125, 1372-1377.	0.8	18
273	Comparative cutoff points for adenosine monophosphate and methacholine challenge testing. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 93, 365-372.	1.0	18
274	Inflammation, glucocorticoids and risk of cardiovascular disease. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 18-19.	3.2	18
275	Effects of intravenous and oral $\beta_2$ -blockade in persistent asthmatics controlled on inhaled corticosteroids. <i>Heart</i> , 2014, 100, 219-223.	2.9	18
276	The Choice of Biologics in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4235-4238.	3.8	18
277	The biochemical effects of high-dose inhaled salbutamol in patients with asthma. <i>European Journal of Clinical Pharmacology</i> , 1989, 36, 357-360.	1.9	17
278	Lung delivery of salbutamol by dry powder inhaler (Turbuhaler <sup>®</sup> ) and small volume antistatic metal spacer (Airomir <sup>®</sup> CFC-free MDI plus NebuChamber <sup>®</sup> ). <i>European Respiratory Journal</i> , 1997, 10, 1820-1823.	6.7	17
279	Adrenal suppression with inhaled corticosteroids. <i>Annals of Allergy, Asthma and Immunology</i> , 2001, 87, 359-361.	1.0	17
280	Antagonism of long-acting $\beta_2$ -adrenoceptor agonism. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 231-245.	2.4	17
281	Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 698-705.	2.4	17
282	A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 305-310.	2.6	17
283	Relationship of Mannitol Challenge to Methacholine Challenge and Inflammatory Markers in Persistent Asthmatics Receiving Inhaled Corticosteroids. <i>Lung</i> , 2012, 190, 513-521.	3.3	17
284	The potential role of direct and indirect bronchial challenge testing to identify overtreatment of community managed asthma. <i>Clinical and Experimental Allergy</i> , 2014, 44, 1240-1245.	2.9	17
285	Blood eosinophils: The forgotten man of inhaled steroid dose titration. <i>Clinical and Experimental Allergy</i> , 2018, 48, 93-95.	2.9	17
286	Impact of nasal polyps on endotype and phenotype in patients with moderate to severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 548-552.	1.0	17
287	Human C-type natriuretic peptide: effects on the haemodynamic and endocrine responses to angiotensin II. <i>Cardiovascular Research</i> , 1995, 29, 108-111.	3.8	17
288	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK <sup>air</sup> real-world data. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2699-2711.	5.7	17

#	ARTICLE	IF	CITATIONS
289	Sex differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline.. Thorax, 1992, 47, 1056-1059.	5.6	16
290	Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease.. Thorax, 1993, 48, 1151-1155.	5.6	16
291	Acute neurohormonal responses to hypoxaemia in man. European Journal of Applied Physiology and Occupational Physiology, 1996, 72, 256-260.	1.2	16
292	Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children. British Journal of Clinical Pharmacology, 2002, 54, 544-547.	2.4	16
293	Paradoxical Trough Effects of Triple Therapy With Budesonide/Formoterol and Tiotropium Bromide on Pulmonary Function Outcomes in COPD. Chest, 2010, 138, 595-604.	0.8	16
294	Think the impossible: $\beta_2$ -blockers for treating asthma. Clinical Science, 2010, 118, 115-120.	4.3	16
295	An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. Npj Primary Care Respiratory Medicine, 2017, 27, 3.	2.6	16
296	Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics. Clinical and Experimental Allergy, 2020, 50, 1140-1147.	2.9	16
297	Beta-adrenoceptor responses to inhaled salbutamol in the elderly.. British Journal of Clinical Pharmacology, 1989, 28, 725-729.	2.4	15
298	Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thorax, 2002, 57, 865-868.	5.6	15
299	Dose-response to salbutamol via a novel palm sized nebuliser (AerodoseR Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolinm Evohalerm) in moderate to severe asthmatics. British Journal of Clinical Pharmacology, 2005, 59, 5-13.	2.4	15
300	Effects of intranasal corticosteroid on nasal adenosine monophosphate challenge in persistent allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 1319-1325.	5.7	15
301	Prescribing of $\beta_2$ -adrenoceptor antagonists in asthma: an observational study. Thorax, 2011, 66, 502-507.	5.6	15
302	Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add-on therapy. British Journal of Clinical Pharmacology, 2013, 75, 93-102.	2.4	15
303	The inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-moderate persistent asthma. Clinical Science, 2014, 127, 635-643.	4.3	15
304	Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma. Journal of Allergy and Clinical Immunology, 2016, 137, 727-733.e1.	2.9	15
305	Real-life small airway outcomes in severe asthma patients receiving biologic therapies. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2907-2909.	3.8	15
306	Repeatability of impulse oscillometry in patients with severe asthma. European Respiratory Journal, 2022, 59, 2101679.	6.7	15

#	ARTICLE	IF	CITATIONS
307	Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade. <i>Cardiovascular Research</i> , 1995, 30, 875-80.	3.8	15
308	Effects of lisinopril on congestive heart failure in normotensive patients with diastolic dysfunction but intact systolic function. <i>European Journal of Clinical Pharmacology</i> , 1995, 49, 15-9.	1.9	14
309	An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 354-359.	2.4	14
310	Dose-response comparison of budesonide dry powder inhalers using adenosine monophosphate bronchial challenge. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 94, 675-681.	1.0	14
311	Airway and systemic effects of soluble and suspension formulations of nebulized budesonide in asthmatic children. <i>Annals of Allergy, Asthma and Immunology</i> , 2009, 103, 436-441.	1.0	14
312	Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 637-644.	2.4	14
313	Impact of Long-Acting Bronchodilators and Exposure to Inhaled Corticosteroids on Mortality in COPD: A Real-Life Retrospective Cohort Study. <i>Lung</i> , 2014, 192, 649-652.	3.3	14
314	Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. <i>European Journal of Clinical Pharmacology</i> , 1989, 37, 49-52.	1.9	14
315	Forced Vital Capacity and Low Frequency Reactance Area Measurements Are Associated with Asthma Control and Exacerbations. <i>Lung</i> , 2022, 200, 301-303.	3.3	14
316	Comparison of parameters of in vitro lymphocyte $\beta_2$ -adrenoceptor function in normal and asthmatic subjects. <i>European Journal of Clinical Pharmacology</i> , 1993, 45, 535-538.	1.9	13
317	$\beta_2$ -Adrenoceptor Regulation and Function in Female Asthmatic Patients Receiving the Oral Combined Contraceptive Pill. <i>Chest</i> , 1998, 113, 278-282.	0.8	13
318	The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 639-642.	2.4	13
319	A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 609-615.	2.4	13
320	The effect of beta2-adrenoceptor haplotypes on bronchial hyper-responsiveness in patients with asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 254-259.	5.7	13
321	Removing nasal valve obstruction in peak nasal inspiratory flow measurement. <i>Annals of Allergy, Asthma and Immunology</i> , 2007, 99, 59-60.	1.0	13
322	Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 355-363.	1.9	13
323	Dose-response for inhaled fluticasone on airway and systemic inflammation in COPD. <i>European Respiratory Journal</i> , 2011, 37, 206-209.	6.7	13
324	Pulmonary arterial stiffening in COPD and its implications for right ventricular remodelling. <i>European Radiology</i> , 2018, 28, 3464-3472.	4.5	13

#	ARTICLE	IF	CITATIONS
325	Inhaled Corticosteroids and COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 899-900.	5.6	13
326	2020 Updated Asthma Guidelines: Clinical utility of fractional exhaled nitric oxide (Feno) in asthma management. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1281-1282.	2.9	13
327	The effects of time and dose on the relative beta 1 and beta 2 adrenoceptor antagonism of betaxolol and atenolol. <i>British Journal of Clinical Pharmacology</i> , 1991, 31, 154-159.	2.4	12
328	Acute Effects of Hypoxaemia and Angiotensin II in the Human Pulmonary Vascular Bed. <i>Pulmonary Pharmacology</i> , 1994, 7, 305-310.	0.6	12
329	Nitric oxide: an important role in the maintenance of systemic and pulmonary vascular tone in man. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 263-266.	2.4	12
330	Comparative trough effects of formoterol and salmeterol on lymphocyte $\beta_2$ -adrenoceptor -regulation and bronchodilatation. <i>European Journal of Clinical Pharmacology</i> , 1999, 55, 431-436.	1.9	12
331	Optimizing Bronchodilator Therapy for COPD. <i>Chest</i> , 2001, 119, 1628-1630.	0.8	12
332	Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 95, 259-265.	1.0	12
333	A proof-of-concept study to assess the putative dose response to topical corticosteroid in persistent allergic rhinitis using adenosine monophosphate challenge. <i>Clinical and Experimental Allergy</i> , 2007, 37, 696-703.	2.9	12
334	Prospective Follow-Up of Novel Markers of Bone Turnover in Persistent Asthmatics Exposed to Low and High Doses of Inhaled Ciclesonide over 12 Months. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1929-1936.	3.6	12
335	Targets for inhaled treatment. <i>Respiratory Medicine</i> , 2000, 94, S13-S16.	2.9	12
336	Effects of Low and High Doses of Inhaled Flunisolide and Triamcinolone Acetonide on Basal and Dynamic Measures of Adrenocortical Activity in Healthy Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 922-925.	3.6	12
337	Comparative effects of angiotensin II on Doppler parameters of left and right heart systolic and diastolic blood flow. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 273-278.	2.4	11
338	Effects of short-term exposure to high-dose inhaled corticosteroids on novel markers of bone metabolism. <i>European Journal of Clinical Pharmacology</i> , 1996, 50, 275-277.	1.9	11
339	Revisiting interactions between hypoxaemia and beta2 agonists in asthma. <i>Thorax</i> , 2001, 56, 506-507.	5.6	11
340	Eosinophils from patients with asthma express higher levels of the pan-leucocyte receptor CD45 and the isoform CD45RO. <i>Clinical and Experimental Allergy</i> , 2003, 33, 936-941.	2.9	11
341	The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 388-392.	2.4	11
342	Inhaled treatment for chronic obstructive pulmonary disease: what's new and how does it fit?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 505-512.	0.5	11

#	ARTICLE	IF	CITATIONS
343	Anti-inflammatory reliever therapy for asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 13-15.	1.0	11
344	Systemic IL-6 and Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1324-1325.	5.6	11
345	Predicting Severe Outcomes in COVID-19. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2582-2584.	3.8	11
346	Impulse oscillometry bronchodilator response and asthma control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3610-3612.	3.8	11
347	Effects of oral and inhaled corticosteroid on lymphocyte $\beta_2$ -adrenoceptor function in asthmatic patients. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 565-568.	2.4	10
348	The Emerging Role of Leukotriene Antagonists in Asthma Therapy. <i>Chest</i> , 1999, 115, 313-316.	0.8	10
349	Continuity of prescribing with inhaled corticosteroids and control of asthma. <i>Pharmacoepidemiology and Drug Safety</i> , 2000, 9, 293-303.	1.9	10
350	Letters to the Editor. <i>Respiratory Medicine</i> , 2000, 94, 177.	2.9	10
351	The skin vasoconstrictor assay does not correlate significantly to airway or systemic responsiveness to inhaled budesonide in asthmatic patients. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 643-647.	1.9	10
352	Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017, 110, 785-792.	0.5	10
353	Problems with asthma following treatment of thyrotoxicosis. <i>British Journal of Diseases of the Chest</i> , 1988, 82, 310-314.	0.5	9
354	A dose-ranging study to evaluate the $\beta_2$ -adrenoceptor selectivity of single doses of betaxolol. <i>British Journal of Clinical Pharmacology</i> , 1990, 30, 119-126.	2.4	9
355	The effects of frusemide and triamterene on the hypokalaemic and electrocardiographic responses to inhaled terbutaline. <i>British Journal of Clinical Pharmacology</i> , 1991, 32, 630-632.	2.4	9
356	Evaluation of in vivo partial $\beta_1/\beta_2$ -agonist activity: a dose-ranging study with carteolol. <i>British Journal of Clinical Pharmacology</i> , 1992, 33, 411-416.	2.4	9
357	An Audit of Hospital Discharge Letters in Patients Admitted with Acute Asthma. <i>Scottish Medical Journal</i> , 1993, 38, 116-119.	1.3	9
358	The effects of lower than conventional doses of oral nadolol on relative $\beta_1/\beta_2$ -adrenoceptor blockade. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 103-108.	2.4	9
359	Effects of oral and inhaled corticosteroids on the hypothalamic-pituitary-adrenal axis. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 104, 713.	2.9	9
360	Comparative In Vivo Lung Delivery of Hydrofluoroalkane-Salbutamol Formulation Via Metered-Dose Inhaler Alone, With Plastic Spacer, or With Cardboard Tube. <i>Chest</i> , 2001, 119, 1018-1020.	0.8	9

#	ARTICLE	IF	CITATIONS
361	Second-Line Controller Therapy for Persistent Asthma Uncontrolled on Inhaled Corticosteroids. <i>Drugs</i> , 2002, 62, 2315-2332.	10.9	9
362	Relationship Between Changes in Quality of Life and Measures of Lung Function and Bronchial Hyper-Responsiveness During High-Dose Inhaled Corticosteroid Treatment in Uncontrolled Asthma. <i>Treatments in Respiratory Medicine</i> , 2003, 2, 433-438.	1.2	9
363	Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 95, 283-290.	1.0	9
364	Comparative safety and efficacy of 2 formulations of fluticasone aqueous nasal spray in persistent allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2009, 102, 76-83.	1.0	9
365	Effects of hydrocortisone on acute $\beta_2$ -adrenoceptor blocker and histamine induced bronchoconstriction. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 717-726.	2.4	9
366	Inhaled corticosteroid dose response in asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 179-185.	1.0	9
367	Anti-interleukin 13 for asthma: stick or twist?. <i>Lancet Respiratory Medicine</i> , 2018, 6, e46-e47.	10.7	9
368	COVID-19: Start with the nose. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1214.	2.9	9
369	Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials. <i>Respiratory Research</i> , 2020, 21, 69.	3.6	9
370	Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model. <i>Clinical and Translational Allergy</i> , 2022, 12, e12128.	3.2	9
371	Evaluation of plasma and urinary salbutamol levels in COPD. <i>European Journal of Clinical Pharmacology</i> , 1996, 51, 91-93.	1.9	8
372	Relative lung delivery of fluticasone propionate via large volume spacer or nebuliser in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 637-641.	1.9	8
373	Effect of levocetirizine on nasal provocation testing with adenosine monophosphate compared with allergen challenge in allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2009, 39, 409-416.	2.9	8
374	A proof-of-concept study to evaluate the anti-inflammatory effects of a novel soluble cyclodextrin formulation of nebulized budesonide in patients with mild to moderate asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2009, 102, 161-167.	1.0	8
375	Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 173-178.e3.	2.9	8
376	Combined Oral and Intranasal Corticosteroid Therapy for Nasal Polyps. <i>Annals of Internal Medicine</i> , 2011, 155, 277.	3.9	8
377	Relationships Between Airway Hyperresponsiveness, Inflammation, and Calibre in Asthma. <i>Lung</i> , 2011, 189, 493-497.	3.3	8
378	Effects of Extra-Fine Inhaled and Oral Corticosteroids on Alveolar Nitric Oxide in COPD. <i>Lung</i> , 2012, 190, 395-401.	3.3	8



#	ARTICLE	IF	CITATIONS
379	Î²2-Adrenoceptor Genotype and Bronchoprotective Subsensitivity with Long-Acting Î²2-Agonists in Asthma. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1386-1387.	5.6	8
380	Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma. Clinical and Experimental Allergy, 2017, 47, 1239-1245.	2.9	8
381	Un-diagnosing persistent adult asthma. European Respiratory Journal, 2017, 50, 1701433.	6.7	8
382	Effects of contrast administration on cardiac MRI volumetric, flow and pulse wave velocity quantification using manual and software-based analysis. British Journal of Radiology, 2018, 91, 20170717.	2.2	8
383	Use of inhaled corticosteroids in asthma and coronavirus disease 2019. Annals of Allergy, Asthma and Immunology, 2020, 125, 503-504.	1.0	8
384	Asthma prescribing according to Arg16Gly beta-2 genotype: a randomised trial in adolescents. European Respiratory Journal, 2021, 58, 2004107.	6.7	8
385	Type 2 Asthma Inflammation and COVID-19: A Double Edged Sword. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1163-1165.	3.8	8
386	Combining low frequency oscillometry and spirometry measurements in relation to asthma control and exacerbations in moderate to severe asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	8
387	Comparison of rhinitis treatments using <sc>MASK</sc>â€airÂ® data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	5.7	8
388	The effects of chronic dosing on the ?1 and ?2-adrenoceptor antagonism of betaxolol and atenolol. European Journal of Clinical Pharmacology, 1991, 40, 467-471.	1.9	7
389	Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers.. British Journal of Clinical Pharmacology, 1995, 40, 313-318.	2.4	7
390	A Repeat Audit of Hospital Discharge Letters in Patients Admitted with Acute Asthma. Scottish Medical Journal, 1997, 42, 19-21.	1.3	7
391	Concomitant occasional use of salbutamol influences bronchoprotective responsiveness afforded by formoterol in patients with the glycine-16 genotype. European Journal of Clinical Pharmacology, 2004, 59, 791-795.	1.9	7
392	An in vivo and in vitro comparison of inhaled steroid delivery via a novel vortex actuator and a conventional valved holding chamber. Annals of Allergy, Asthma and Immunology, 2007, 98, 471-479.	1.0	7
393	Impact of Left Ventricular Hypertrophy on Survival in Chronic Obstructive Pulmonary Disease. Lung, 2015, 193, 487-495.	3.3	7
394	Effects of Adding Tiotropium or Acclidinium as Triple Therapy Using Impulse Oscillometry in COPD. Lung, 2016, 194, 259-266.	3.3	7
395	Disconnection of pulmonary and systemic arterial stiffness in COPD. International Journal of COPD, 2018, Volume 13, 1755-1765.	2.3	7
396	Airwave oscillometry and patient-reported outcomes in persistent asthma. Annals of Allergy, Asthma and Immunology, 2020, 124, 289-290.	1.0	7

#	ARTICLE	IF	CITATIONS
397	The comparative safety/efficacy ratio of HFA-BDP. <i>Respiratory Medicine</i> , 2000, 94, S21-S26.	2.9	7
398	Potentially hazardous co-prescribing of beta-adrenoceptor antagonists and agonists in the community. <i>British Journal of General Practice</i> , 1996, 46, 423-5.	1.4	7
399	Oscillometry bronchodilator response in adult moderate to severe eosinophilic asthma patients: A prospective cohort study. <i>Clinical and Experimental Allergy</i> , 2022, 52, 1118-1120.	2.9	7
400	The beta-agonist controversy: fact or fiction?. <i>Clinical and Experimental Allergy</i> , 1992, 22, 659-664.	2.9	6
401	Extrapulmonary $\beta_2$ -responses to intravenous salbutamol during the menstrual cycle. <i>European Journal of Clinical Pharmacology</i> , 1994, 46, 511-5.	1.9	6
402	Mometason Furoate Levels. <i>Chest</i> , 2001, 120, 1034-1035.	0.8	6
403	Sustained bronchoprotection with montelukast but not formoterol as add on therapy in asthmatics with the homozygous glycine 16 $\beta_2$ adrenoceptor genotype. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S157-S157.	2.9	6
404	Evaluation of an Abbreviated Adenosine Monophosphate Bronchial Challenge. <i>Chest</i> , 2005, 127, 2222-2225.	0.8	6
405	Real-life effect of long-acting $\beta_2$ -agonist withdrawal in patients with controlled step 3 asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 430-431.	1.0	6
406	Assessment of proximal pulmonary arterial stiffness using magnetic resonance imaging: effects of technique, age and exercise. <i>BMJ Open Respiratory Research</i> , 2016, 3, e000149.	3.0	6
407	A pragmatic approach to simplify inhaler therapy for COPD. <i>Lancet Respiratory Medicine</i> , 2017, 5, 679-681.	10.7	6
408	Does unified allergic airway disease impact on lung function and type 2 biomarkers?. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 75.	2.0	6
409	Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs . dry powder inhaler. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 729-736.	2.4	6
410	Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 413.	2.9	6
411	Intolerance to Angiotensin Converting Enzyme Inhibitors in Asthma and the General Population: A UK Population-Based Cohort Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3431-3439.e4.	3.8	6
412	An audit of acute asthma admissions to a respiratory unit. <i>Health Bulletin</i> , 1992, 50, 389-98.	0.1	6
413	Peak inspiratory flow rate is more sensitive than acoustic rhinometry or rhinomanometry in detecting corticosteroid response with nasal histamine challenge. <i>Rhinology</i> , 2003, 41, 16-20.	1.3	6
414	A Case of Eosinophilic Pleural Effusion Complicating Multiple Myeloma. <i>Scottish Medical Journal</i> , 1988, 33, 278-278.	1.3	5

#	ARTICLE	IF	CITATIONS
415	A comparison of the effects of prednisolone and mianserin on ventilatory, exercise and psychometric parameters in patients with chronic obstructive pulmonary disease. <i>European Journal of Clinical Pharmacology</i> , 1995, 48, 13-8.	1.9	5
416	Effect of exogenous female sex-steroid hormones on $\beta_2$ -adrenoceptors in healthy males. <i>European Journal of Clinical Pharmacology</i> , 1997, 52, 281-283.	1.9	5
417	Asthma management with HFA-BDP (Qvar <sup>®</sup> , <sup>®</sup> ). <i>British Journal of Hospital Medicine</i> , 1999, 60, 263-270.	0.2	5
418	Combined mediator antagonism for allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2004, 59, 276-279.	5.7	5
419	Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline?. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 96, 640-642.	1.0	5
420	Proof of concept study to evaluate step-down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 128-131.	2.4	5
421	Tiotropium in Asthma. <i>New England Journal of Medicine</i> , 2012, 367, 2552-2553.	27.0	5
422	Comparative evaluation of nasal blood flow and airflow in the decongestant response to oxymetazoline. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 108, 77-80.	1.0	5
423	Corticosteroid Protection Against COVID-19: Begin with the Nose. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3941-3943.	3.8	5
424	The effect of pindolol on creatine kinase is not due to beta $\beta_2$ -adrenoceptor partial agonist activity [letter; comment]. <i>British Journal of Clinical Pharmacology</i> , 1991, 31, 723-724.	2.4	4
425	Fenoterol and asthma mortality. <i>Lancet, The</i> , 1998, 352, 486-487.	13.7	4
426	Lost in the Labyrinth of End Points. <i>Chest</i> , 2001, 120, 323-324.	0.8	4
427	Asthma exacerbations and sputum eosinophil counts. <i>Lancet, The</i> , 2003, 361, 1302-1303.	13.7	4
428	Designer Inhaled Corticosteroids. <i>Chest</i> , 2005, 128, 1081-1084.	0.8	4
429	Influence of $\beta_2$ -adrenergic receptor polymorphism on methacholine hyperresponsiveness in asthmatic patients. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 110, 161-164.	1.0	4
430	Explaining differential effects of tiotropium on mortality in COPD. <i>Thorax</i> , 2013, 68, 589-590.	5.6	4
431	Influence of $\beta_2$ -adrenoceptor 16 genotype on propranolol-induced bronchoconstriction in patients with persistent asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 112, 475-476.	1.0	4
432	The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK. <i>International Journal of COPD</i> , 2016, Volume 11, 2851-2858.	2.3	4

#	ARTICLE	IF	CITATIONS
433	Effects of the inverse alpha $\beta$ -agonist doxazosin in allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2016, 46, 696-704.	2.9	4
434	Sensitivity of Lung Resistance and Compliance to Beta-Blocker Induced Bronchoconstriction and Long Acting Beta-Agonist Withdrawal in COPD. <i>Lung</i> , 2018, 196, 15-18.	3.3	4
435	Eosinophil paradox with mepolizumab in chronic rhinosinusitis with nasal polyposis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 683.	2.9	4
436	Tocilizumab for severe COVID-19 pneumonia. <i>Lancet Rheumatology</i> , The, 2020, 2, e660.	3.9	4
437	Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. <i>Respiratory Research</i> , 2020, 21, 128.	3.6	4
438	Adrenal insufficiency after treatment with fluticasone. <i>BMJ: British Medical Journal</i> , 2002, 325, 836a-836.	2.3	4
439	Development of persistent late onset asthma following treatment with captopril. <i>European Respiratory Journal</i> , 1989, 2, 586-8.	6.7	4
440	Short-term repeatability and correlates of laboratory measures of nasal function in patients with seasonal allergic rhinitis. <i>Rhinology</i> , 2002, 40, 66-8.	1.3	4
441	Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma. <i>European Journal of Clinical Pharmacology</i> , 1990, 39, 281-285.	1.9	3
442	The Effects of Enalapril and Spironolactone on Terbutaline-Induced Hypokalemia. <i>Chest</i> , 1992, 102, 91-95.	0.8	3
443	$\beta_2$ -adrenoceptor subtypes mediating the airways response to BRL 35135 in man. <i>British Journal of Clinical Pharmacology</i> , 1993, 36, 567-571.	2.4	3
444	Does use or withdrawal of long-acting $\beta_2$ -adrenoceptor induce desensitisation?. <i>Lancet</i> , The, 1998, 351, 67.	13.7	3
445	Reproducibility of nasal function measurements with histamine and adenosine monophosphate nasal challenge testing in patients with allergic rhinitis. <i>Allergy International</i> , 2003, 52, 155-160.	3.3	3
446	Lower thresholds for bronchial challenge testing. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2004, 59, 1125-1126.	5.7	3
447	Intranasal and inhaled corticosteroids in allergic rhinitis and asthma. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 447-448.	2.4	3
448	Pharmacological management—oral treatment. <i>BMJ: British Medical Journal</i> , 2006, 332, 1497-1499.	2.3	3
449	Proof-of-concept evaluation of trough airway hyper-responsiveness following regular racemic or levosalbutamol in genotype-stratified steroid-treated persistent asthmatic patients. <i>Clinical Science</i> , 2014, 126, 75-83.	4.3	3
450	$\beta_2$ -Adrenergic receptor Gly16Arg polymorphism and impaired asthma control in corticosteroid-treated asthmatic adults. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 114, 421-423.	1.0	3

#	ARTICLE	IF	CITATIONS
451	IMPLICATION OF ALTERNATIVE MINIMAL CLINICALLY IMPORTANT DIFFERENCE THRESHOLD ESTIMATION METHODS ON TECHNOLOGY ASSESSMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 371-375.	0.5	3
452	From mouse to man: predicting biased effects of beta-blockers in asthma. <i>British Journal of Pharmacology</i> , 2016, 173, 248-249.	5.4	3
453	Inhaled corticosteroid dose-response on blood eosinophils in asthma. <i>Lancet Respiratory Medicine</i> , 2016, 4, e1.	10.7	3
454	Is Gly16Arg $\beta$ 2 Receptor Polymorphism Related to Impulse Oscillometry in a Real-Life Asthma Clinic Setting?. <i>Lung</i> , 2016, 194, 267-271.	3.3	3
455	Allopurinol in Patients with Pulmonary Hypertension Associated with Chronic Lung Disease. <i>International Journal of COPD</i> , 2020, Volume 15, 2015-2024.	2.3	3
456	Criteria for Airway Oscillometry Reversibility in Asthma. <i>Chest</i> , 2020, 158, 1282-1283.	0.8	3
457	Emerging Pharmacotherapy for Covid-19. <i>Journal of the Royal College of Physicians of Edinburgh</i> , 2020, 50, 133-137.	0.6	3
458	Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. <i>International Journal of COPD</i> , 2020, Volume 15, 99-106.	2.3	3
459	Inhaled corticosteroids and angiotensin-converting enzyme-2 in COPD. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1117.	2.9	3
460	Articles. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 2125-2126.	5.6	3
461	BUDESONIDE DOSE-RESPONSE IN MILD PERSISTENT ASTHMA. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1188-1189.	5.6	3
462	The ISOLDE trial. Side effects with inhaled steroids should not be forgotten. <i>BMJ: British Medical Journal</i> , 2000, 321, 1349.	2.3	3
463	Clinical importance of the Step 3 choice in asthma. <i>Thorax</i> , 2006, 61, 180-1; author reply 181.	5.6	3
464	High-dose budesonide for early COVID-19. <i>Lancet</i> , 2021, 398, 2147.	13.7	3
465	MEASUREMENT OF NORMAL HUMAN AIRWAYS RESPONSE TO $\beta$ -ADRENOCEPTOR STIMULATION USING A FORCED OSCILLATION TECHNIQUE. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1991, 16, 187-191.	1.5	2
466	Use of Pulsed-Wave Doppler Echocardiography to Measure Changes in MPAP: To the Editor. <i>Chest</i> , 1997, 111, 1470.	0.8	2
467	Reaudit of Acute Asthma Admissions Using a Severity Marker Stamp and Determinants of an Outcome Measure. <i>Scottish Medical Journal</i> , 1997, 42, 49-52.	1.3	2
468	Influences on plasma cortisol of different formulations of beclomethasone dipropionate. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 381-381.	2.4	2

#	ARTICLE	IF	CITATIONS
469	Fluticasone propionate/salmeterol combination. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 746.	2.9	2
470	Fluticasone and Cortisol Measurements. <i>Chest</i> , 2001, 119, 984.	0.8	2
471	An Own GOAL or a Real Breakthrough?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 1060-1060.	5.6	2
472	In vitro synergism of inhaled corticosteroid and long-acting $\beta_2$ -agonist is not translated clinically in vivo. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 880.	2.9	2
473	Evaluating the Effects of "Triple Therapy" With Inhaled Corticosteroids, Long-Acting $\beta_2$ -Agonists, and Leukotriene Modifiers in Asthma. <i>Chest</i> , 2006, 130, 301-302.	0.8	2
474	Comment on: "Obtaining concomitant control of allergic rhinitis and asthma with intranasal corticosteroid?". <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 1214-1214.	5.7	2
475	P181 Better asthma control with montelukast than salmeterol in Arg-16 homozygous children with asthma. <i>Thorax</i> , 2010, 65, A154-A154.	5.6	2
476	Effects of intranasal salmeterol and fluticasone given alone and in combination in persistent allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 108, 54-59.	1.0	2
477	Systemic safety of fluticasone furoate/vilanterol combination. <i>Thorax</i> , 2013, 68, 1165.1-1165.	5.6	2
478	Biomarkers to predict inhaled corticosteroid response. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 515.	2.9	2
479	Debate on long-acting $\beta_2$ agonists for asthma: they think it's all over. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, e14-e15.	10.7	2
480	FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1082-1082.	5.6	2
481	Adrenal suppression with inhaled corticosteroids: the seed and the soil. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, e19.	10.7	2
482	Bronchoprotective tolerance with inhaled corticosteroid/long-acting $\beta_2$ -agonist treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 873.	2.9	2
483	Pragmatic evaluation of inhaled corticosteroid particle size formulations on asthma control. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1321-1327.	2.9	2
484	Allergic burden and response to dupilumab. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 822.	3.8	2
485	End-point selection to determine the airway:systemic ratio of inhaled corticosteroids in asthma. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2401-2402.	2.4	2
486	THE PROBLEM OF DOSE-RESPONSE AND THERAPEUTIC RATIO OF INHALED STEROIDS. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 1758-1759.	5.6	2

#	ARTICLE	IF	CITATIONS
487	Asthma control. <i>Lancet, The</i> , 1994, 344, 760.	13.7	2
488	Mepolizumab response in severe chronic rhinosinusitis with nasal polyps is dissociated from blood eosinophil levels. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1817.	2.9	2
489	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). <i>Trials</i> , 2022, 23, 307.	1.6	2
490	Hypoxaemia and the Renin-Angiotensin System: New Answers for Old Questions. <i>Pulmonary Pharmacology</i> , 1994, 7, 279-284.	0.6	1
491	Use of Fluticasone in Asthma. <i>Chest</i> , 2000, 117, 611-612.	0.8	1
492	Therapeutic ratio of inhaled fluticasone. <i>Thorax</i> , 2000, 55, 251a-251.	5.6	1
493	Inhaled corticosteroids and bone density. <i>Lancet, The</i> , 2000, 356, 425.	13.7	1
494	Budesonide/Formoterol Combination. <i>Drugs</i> , 2001, 61, 79-80.	10.9	1
495	Systemic bioavailability of fluticasone propionate. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 457-458.	2.4	1
496	Bronchodilator Reversibility to Albuterol Predicts Bronchodilator Response to Salmeterol. <i>Chest</i> , 2002, 121, 1382.	0.8	1
497	Effects of salmeterol on smooth muscle versus inflammatory outcomes. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 223.	2.9	1
498	Decongestant effects of antihistamines: A class effect?. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 653.	2.9	1
499	Pharmacological interventions and outcome measurements in the unified airway. <i>Clinical and Experimental Allergy Reviews</i> , 2005, 5, 26-31.	0.3	1
500	COMBINATION THERAPY WITH A LONG-ACTING $\beta_2$ -AGONIST AND AN INHALED CORTICOSTEROID AS INITIAL MAINTENANCE TREATMENT IN ASTHMA. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 94, 410-411.	1.0	1
501	Guidelines to establish relative potency are not in touch with reality. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 834-835.	2.4	1
502	Adverse Effects of Long-Acting Beta-Agonists on Airway Hyperresponsiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 49, 501-502.	2.9	1
503	Uncorrected nitric oxide levels in mild asthmatics produce flawed interpretation. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1255.	2.9	1
504	Relationship of large and small airway response with inhaled corticosteroid to asthma control. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 111, 140-142.	1.0	1



#	ARTICLE	IF	CITATIONS
505	Clinical relevance of house dust mite immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 288.	2.9	1
506	Triple inhaler therapy for COPD. <i>Thorax</i> , 2015, 70, 991-991.	5.6	1
507	Nasal endoscopy to characterize sinonasal disease. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 212.	2.9	1
508	Letter to the editor: Comparing pace and speed in the pulmonary circulation?. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H949-H949.	3.2	1
509	Improvements with sublingual house dust mite immunotherapy in allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 634-635.	2.9	1
510	Of mice and men—the curious tale of $\beta_2$ blockers in asthma. <i>Lancet Respiratory Medicine</i> , 2016, 4, 89-91.	10.7	1
511	Impact of Spacers on Therapeutic Ratio with Inhaled Corticosteroids. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1163.	3.8	1
512	Drug-device interaction for systemic effects of fluticasone in patients with asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 194.	1.0	1
513	Asthma Step-Down Strategies: Perhaps the Patient Should Decide?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 644-645.	3.8	1
514	Does the asthma visual analog scale relate to the Asthma Control Questionnaire?. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 533-535.	1.0	1
515	Tolerability of Bisoprolol on Domiciliary Spirometry in COPD. <i>Lung</i> , 2018, 196, 11-14.	3.3	1
516	Non-canonical $\beta_2$ -receptor signaling. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1735.	2.9	1
517	Single Triple vs Dual Inhaler Therapy. <i>Chest</i> , 2019, 155, 1078-1079.	0.8	1
518	Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD. <i>European Respiratory Journal</i> , 2019, 53, 1802420.	6.7	1
519	Systemic effects of fluticasone on blood eosinophils in bronchiectasis. <i>European Respiratory Journal</i> , 2020, 56, 2002005.	6.7	1
520	Making simple things complicated using anti-inflammatory reliever therapy. <i>European Respiratory Journal</i> , 2020, 55, 2000267.	6.7	1
521	Systemic potency of fluticasone in asthma. <i>European Respiratory Journal</i> , 2020, 55, 2000104.	6.7	1
522	Optimal asthma control in African American children with asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2121.	3.8	1

#	ARTICLE	IF	CITATIONS
523	Observational Data With Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist May Not Reflect Current Practice With Single Triple Inhalers. <i>Chest</i> , 2020, 157, 1045.	0.8	1
524	Relative lung dose from antistatic valved holding chambers. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1166.	3.8	1
525	Low-Grade B Cell Lymphoproliferative Disorder Masquerading as Chronic Rhinosinusitis. <i>Sinusitis</i> , 2021, 5, 1-4.	0.8	1
526	Inhaled triple therapy and airway hyperresponsiveness in persistent asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 597-598.	1.0	1
527	Effect of controller prescribing according to rs1042713 genotype on asthma related quality of life in young people (PACT): a randomized controlled trial. , 2020, , .		1
528	Revisiting interactions between hypoxaemia and $\beta_2$ agonists in asthma. <i>Thorax</i> , 2001, 56, 506-507.	5.6	1
529	Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy. <i>Lancet Respiratory Medicine</i> , 2021, , .	10.7	1
530	Pragmatic reappraisal of long-acting muscarinic antagonists at steps 4 and 5 for persistent adult asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 274-275.	1.0	1
531	Bioavailability of salbutamol.. <i>Thorax</i> , 1994, 49, 1183-1183.	5.6	0
532	Salmeterol in smokers with COPD.. <i>Thorax</i> , 1996, 51, 110-110.	5.6	0
533	Letter to the Editor. <i>Respiratory Medicine</i> , 2001, 95, 160-161.	2.9	0
534	The role of long-acting $\beta_2$ -agonists in patients uncontrolled on inhaled steroids alone - a pharmacological approach. <i>Clinical and Experimental Allergy Reviews</i> , 2001, 1, 23-28.	0.3	0
535	COMPARABLE EFFICACY OF ADMINISTRATION WITH FACE MASK OR MOUTHPIECE OF NEBULIZED BUDESONIDE SUSPENSION FOR INFANTS AND YOUNG CHILDREN WITH PERSISTANT ASTHMA. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 1277-1278.	5.6	0
536	Duration of Steroid Therapy Determines Dose-Response Effect. <i>Chest</i> , 2002, 121, 306-307.	0.8	0
537	Evaluation of surrogate inflammatory markers for optimizing inhaled corticosteroid therapy in a real-life clinical setting. <i>Allergology International</i> , 2003, 52, 71-75.	3.3	0
538	LUNG BIOAVAILABILITY OF SPACERS. <i>Annals of Allergy, Asthma and Immunology</i> , 2003, 90, 674.	1.0	0
539	H1-Antihistamines. <i>New England Journal of Medicine</i> , 2005, 352, 1155-1157.	27.0	0
540	Respiratory Symptoms and Inflammation After a Smoking Banâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 359.	7.4	0

#	ARTICLE	IF	CITATIONS
541	Long-Acting $\beta_2$ Agonists and Inhaled Corticosteroids in Asthma. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 853-854.	5.6	0
542	Levalbuterol kinetics. Journal of Allergy and Clinical Immunology, 2009, 123, 275.	2.9	0
543	Review: Tiotropium mist inhaler increases mortality in chronic obstructive pulmonary disease. Annals of Internal Medicine, 2011, 155, JC4.	3.9	0
544	Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone and salmeterol: a reply. British Journal of Clinical Pharmacology, 2011, 72, 355-356.	2.4	0
545	Comparison of Montelukast Versus Salmeterol as Add-On to Inhaled Fluticasone in at-Risk Asthmatic Children Possessing the Homozygous Arginine-16 B2-Adrenoceptor Genotype- a Randomized Controlled Trial. Pediatric Research, 2011, 70, 17-17.	2.3	0
546	P257 Effects of extra-fine inhaled and oral corticosteroids on alveolar nitric oxide in COPD. Thorax, 2011, 66, A172-A172.	5.6	0
547	Cardiac beta-2 adrenoceptor responses to formoterol and associated corticosteroid interactions. Annals of Allergy, Asthma and Immunology, 2012, 108, 68.	1.0	0
548	Adrenal suppression with fluticasone furoate. Annals of Allergy, Asthma and Immunology, 2013, 110, 213.	1.0	0
549	Lack of clinically relevant differences between combination therapy and monotherapy in COPD. European Respiratory Journal, 2014, 43, 1204-1204.	6.7	0
550	Adrenal Suppression With Mometasone Furoate/Formoterol. Chest, 2014, 145, 1175-1176.	0.8	0
551	Tiotropium in asthma. Lancet Respiratory Medicine, the, 2015, 3, e16-e17.	10.7	0
552	Reappraisal of the clinical effect of mepolizumab. Lancet Respiratory Medicine, the, 2017, 5, e20.	10.7	0
553	Inhaled triple therapy in chronic obstructive pulmonary disease. Lancet, The, 2018, 392, 1112-1113.	13.7	0
554	Real-World Studies in Infrequently Exacerbating Patients With COPD. Chest, 2019, 156, 415-416.	0.8	0
555	Resistance Heterogeneity and Small Airway Asthma Phenotype. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1441-1442.	5.6	0
556	Differences in asthma control and lung function in relation to allergic status. European Respiratory Journal, 2019, 53, 1802102.	6.7	0
557	Don't Forget about Facilitatory Effects of Corticosteroids on $\beta_2$ -Adrenoceptors in Acute Asthma. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1743-1743.	5.6	0
558	Dupilumab for nasal polyposis. Lancet, The, 2020, 396, 233.	13.7	0

#	ARTICLE	IF	CITATIONS
559	Diagnosing adrenal insufficiency using ACTH stimulation test. <i>European Respiratory Journal</i> , 2020, 56, 2001478.	6.7	0
560	Pneumonia Due to Inhaled Corticosteroids in COPD. <i>Chest</i> , 2020, 157, 1683-1684.	0.8	0
561	How bad is the SAD phenotype in relation to asthma control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 427.	3.8	0
562	Normal spirometry equates to normal impulse oscillometry in healthy subjects. <i>Respiratory Research</i> , 2021, 22, 96.	3.6	0
563	Considerations of a real life pragmatic clinical trial in adolescent asthma. <i>European Respiratory Journal</i> , 2021, 58, 2100461.	6.7	0
564	THE STEP 3 DILEMMA FOR MODERATE PERSISTENT ASTHMA. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1022-1023.	5.6	0
565	The GP's role in allergic rhinitis. <i>Practitioner</i> , 2003, 247, 418-23.	0.3	0
566	Combined medical and surgical therapy for chronic rhinosinusitis with nasal polyposis. <i>Lancet Respiratory Medicine</i> , 2022, 10, e38.	10.7	0